Mostrar el registro sencillo del ítem

dc.contributor.authorFernández Ochoa, Álvaro 
dc.contributor.authorQuirantes-Piné, Rosa
dc.contributor.authorBorras Linares, María Isabel 
dc.contributor.authorGemperline, David
dc.contributor.authorPRECISESADS Clinical Consortium
dc.contributor.authorAlarcón Riquelme, Marta Eugenia 
dc.contributor.authorBeretta, Lorenzo
dc.contributor.authorSegura Carretero, Antonio 
dc.date.accessioned2025-03-19T12:57:09Z
dc.date.available2025-03-19T12:57:09Z
dc.date.issued2018-09-11
dc.identifier.citationPublished version: Fernández Ochoa, Álvaro et al. Journal of Pharmaceutical and Biomedical Analysis Volume 162, 5 January 2019, Pages 82-90. https://doi.org/10.1016/j.jpba.2018.09.021es_ES
dc.identifier.urihttps://hdl.handle.net/10481/103191
dc.descriptionThe work described has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115565, the resources for which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution. The author IBL gratefully acknowledges the Spanish Ministry of Economy and Competitiveness (MINECO) in association with the European Social Fund (FSE) for the contract PTQ-13-06429, the author AFO received support from the Spanish Ministry of Education, Culture and Sports (FPU grant 14/03992).es_ES
dc.description.abstractSystemic Sclerosis (SSc) is a chronic autoimmune disease whose origin and pathogenesis are not yet well known. Recent studies are allowing a better definition of the disease. However, few studies have been performed based on metabolomics. In this way, this study aims to find altered metabolites in SSc patients in order to improve their diagnosis, prognosis and treatment. For that, 59 SSc patients and 28 healthy volunteers participated in this study. Urine and plasma samples were analyzed by a fingerprinting metabolomic approach based on HPLC-ESI-QTOF-MS. We observed larger differences in urine than plasma metabolites. The main deregulated metabolic families in urine were acylcarnitines, acylglycines and metabolites derived from amino acids, specifically from proline, histidine and glutamine. These results indicate perturbations in fatty acid beta oxidation and amino acid pathways in scleroderma patients. On the other hand, the main plasma biomarker candidate was 2-arachidonoylglycerol, which is involved in the endocannabinoid system with potential implications in the induction and propagation of systemic sclerosis and autoimmunity.es_ES
dc.description.sponsorshipEuropean Union’s Seventh Framework Programme (FP7/2007-2013) 115565es_ES
dc.description.sponsorshipEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)es_ES
dc.description.sponsorshipSpanish Ministry of Economy and Competitiveness (MINECO)es_ES
dc.description.sponsorshipEuropean Social Fund (FSE) PTQ-13-06429es_ES
dc.description.sponsorshipSpanish Ministry of Education, Culture and Sports (FPU grant 14/03992)es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMetabolomicses_ES
dc.subjectHPLC-ESI-QTOF-MSes_ES
dc.subjectSystemic Sclerosises_ES
dc.subjectbiomarkeres_ES
dc.subjectacylcarnitineses_ES
dc.subject2-arachidonoylglyceroles_ES
dc.titleUrinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients.es_ES
dc.typejournal articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/115565es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.jpba.2018.09.021
dc.type.hasVersionSMURes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional